CORONA Remedies Limited (NSE:CORONA)

Market Cap	121.64B
Revenue (ttm)	14.03B +20.1%
Net Income	1.85B +31.6%
EPS	30.27 +31.7%
Shares Out	61.16M
PE Ratio	65.71
Forward PE	48.75
Dividend	10.00 (0.50%)
Ex-Dividend Date	Jun 19, 2026

Volume	18,333
Open	2,020.20
Previous Close	2,004.10
Day's Range	1,970.00 - 2,039.80
52-Week Range	1,336.60 - 2,100.70
Beta	n/a
Analysts	Strong Buy
Price Target	1,929.00 (-3.01%)
Earnings Date	Aug 14, 2026

About CORONA Remedies

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 5,153
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CORONA

Financial Performance

In fiscal year 2026, CORONA Remedies's revenue was 14.03 billion, an increase of 17.28% compared to the previous year's 11.96 billion. Earnings were 1.85 billion, an increase of 23.88%.

Analyst Summary

According to 3 analysts, the average rating for CORONA stock is "Strong Buy." The 12-month stock price target is ₹1,929, which is a decrease of -3.01% from the latest price.

Price Target

₹1,929

(-3.01% downside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 7, 2026

Data Sources Report a data error